Matrix metalloproteinases and diabetic foot ulcers: The ratio of MMP-1 to TIMP-1 is a predictor of wound healing

Diabetic Medicine

Volumn 25, Issue 4, 2008, Pages 419-426

  Muller, M ^a   Trocme, C ^a   Lardy, B ^a   Morel, F ^a   Halimi, S ^a   Benhamou, P Y ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Diabetic foot ulcer; Matrix metalloproteinase; Wound healing

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; NEUTROPHIL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC FOOT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; EXTRACELLULAR MATRIX; FEMALE; FOLLOW UP; FRANCE; HUMAN; INFLAMMATORY CELL; MALE; PROTEIN FUNCTION; ROC CURVE; SENSITIVITY AND SPECIFICITY; WOUND FLUID; WOUND HEALING; WOUND HEALING IMPAIRMENT;

AGED; AGED, 80 AND OVER; BODY FLUIDS; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; WOUND HEALING;

EID: 41749096554     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02414.x     Document Type: Article

References (29)

1. Armstrong DG, Jude EB. The role of matrix metalloproteinases in wound healing. J Am Podiatr Med Assoc 2002 92 : 12 18.
2. Ravanti L, Kahari VM. Matrix metalloproteinases in wound repair (Review). Int J Mol Med 2000 6 : 391 407.
3. Lobmann R, Schultz G, Lehnert H. Proteases and the diabetic foot syndrome: mechanisms and therapeutic implications. Diabetes Care 2005 28 : 461 471.
4. Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997 272 : 28823 28825.
5. Soo C, Shaw WW, Zhang X, Longaker MT, Howard EW, Ting K. Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg 2000 105 : 638 647.
6. Moses MA, Marikovsky M, Harper JW. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem 1996 60 : 379 386.
7. Baker EA, Leaper DJ. Profile of matrix metalloproteinases and their tissue inhibitors in intraperitoneal drainage fluid: relationship to wound healing. Wound Rep Reg 2003 11 : 268 274.
8. Trengove NJ, Stacey MC, Macauley S, Bennett N, Gibson J, Burslem F et al. Analysis of the acute and chronic wounds environments: the role of proteases and their inhibitors. Wound Rep Reg 1999 7 : 442 452.
9. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contain elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993 101 : 64 68.
10. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK. Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 1996 107 : 743 748.
11. Yager DR, Stephen MC, Ward SI, Olutoye OO, Diegelmann RF, Cohen IK. Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors. Wound Rep Reg 1997 5 : 23 32.
12. Nwomeh BC, Liang HX, Cohen IK, Yager DR. MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res 1999 81 : 189 195.
13. Vaalamo M, Mattila L, Johansson N, Kariniemi AL, Karjalainen-Lindsberg ML, Kahari VM et al. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol 1997 109 : 96 101.
14. Bullen EC, Longaker MT, Updike DL, Benton R, Ladin D, Hou Z et al. Tissue inhibitor of metalloproteinases-1 is decreased and activated gelatinases are increased in chronic wounds. J Invest Dermatol 1995 104 : 236 240.
15. Vaalamo M, Weckroth M, Puolakkainen P, Kere J, Saarinen P, Lauharanta J et al. Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. Br J Dermatol 1996 135 : 52 59.
16. Ladwig GP, Robson MC, Liu R, Kuhn A, Muir DF, Schulz GS. Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Rep Reg 2002 10 : 26 37.
17. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Rep Reg 2000 8 : 13 25.
18. Piaggesi A, Viacava P, Rizzo L, Naccarato G, Baccetti F, Romanelli M et al. Semiquantitative analysis of the histopathological features of the neuropathic foot ulcer. Diabetes Care 2003 26 : 3123 3128.
19. Lobmann R, Ambrosch A, Schultz G, Waldmann K, Schiweck S, Lehnert H. Expression of matrix-metalloproteinase and their inhibitors in the wounds of diabetic and non-diabetic patients. Diabetologia 2002 45 : 1011 1016.
20. Barro C, Romanet JP, Fdili A, Guillot M, Morel F. Gelatinase concentration in tears of corneal-grafted patients. Current Eye Research 1998 17 : 174 182.
21. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985 150 : 76 85.
22. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003 26 : 1879 1882.
23. Bourd-Boittin K, Fanchon S, Septier D, Menashi S, Goldberg M. Métalloprotéases et inhibiteurs de métalloprotéases au cours de l'odontogénèse. Rôle biologique des sous-produits de dégradation matricielle. Les Cahiers de l'ADF 2004 16-17 : 46 55.
24. Nalbone G, Alessi MC, Juhan-Vague I. Système fibrinolytique, métalloprotéases et pathologie vasculaire. Médecine/ Sciences 2001 17 : 170 176.
25. Ågren M. Matrix metalloproteinases (MMPs) are required for re-epithelialization of cutaneous wounds. Arch Dermatol Res 1999 291 : 583 590.
26. Ågren M, Mirastschijski U, Karlsmark T, Saarialho-Kere U. Topical synthetic inhibitor of matrix metalloproteinases delays epidermal regeneration of human wounds. Exp Dermatol 2001 10 : 337 348.
27. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003 200 : 448 464.
28. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG, Parks WC. The activity of Collagenase-1 is required for keratinocyte migration on a type 1 collagen matrix. J Cell Biol 1997 137 : 1445 1457.
29. Lobmann R, Zemlin C, Motzkau M, Reschke K, Lehnert H. Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing. J Diabetes Complications 2006 20 : 329 335.